SumayahJamalMD

Physician

Dr. Jamal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
166 5th Ave
New York, NY 10010
Phone+1 212-229-0333

Fax+1 646-218-4133

NYU Grossman School of MedicineResidency, Dermatology, 1995 - 1998
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1994 - 1995
New York University School of MedicineClass of 1994

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Start of enrollment: 2020 Feb 18
Active, not recruiting
Phase 1, Phase 2

PubMed

1 citations
Macrocystis pyrifera ferment-containing creams for optimizing facial skin rejuvenation.
Michael Gold, Yoon-Soo Cindy Bae, David J Goldberg, Sumayah Jamal, Amy B Lewis
Journal of Cosmetic Dermatology. 2023-12-01
15 citations
Endothelin-1 in the tumor microenvironment correlates with melanoma invasion.
Luis Chiriboga, Shane Meehan, Iman Osman, Michael Glick, Gelo de la Cruz
Melanoma Research. 2016-06-01
7 citations
Akt and PI3K-dependent but CREB-independent upregulation of MCAM by endothelin-3 in human melanocytes.
Brittny H. Williams, Robert J. Schneider, Sumayah Jamal
Melanoma Research. 2014-08-01

9 Dark Spot Treatments That Really Work, According to DermatologistsSeptember 6th, 2019
ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in Combination with KEYTRUDA(R) (Pembrolizumab) for Advanced Solid TumorsFebruary 4th, 2019